Data_Sheet_1_Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study.pdf
Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltrials.gov, identifier: NCT01582061).
Methods: Adults with active CD previously untreated with pasireotide were enrolled; pasireotide sc was initiated at 600 μg twice daily (bid; EU countries) or 900 μg bid (non-EU countries; 600 μg bid in patients with impaired glucose metabolism). Pasireotide dose could be adjusted in 300 μg increments/decrements to a maximum of 900 μg bid or minimum of 300 μg bid for sustained urinary free cortisol (UFC) normalization/tolerability issues. Primary objective: document the safety of pasireotide sc in patients with CD. Key secondary objectives: assess the proportion of patients with mean UFC (mUFC) not exceeding the upper limit of normal (ULN) and changes from baseline in clinical signs/symptoms and quality of life (QoL) to weeks 12, 24, and 48.
Results: One hundred and four patients received pasireotide: female, n = 84 (80.8%); median duration of pasireotide exposure, 25.1 weeks; median (range) baseline mUFC, 321.2 nmol/24 h (142–10,920; 2.3 × ULN [1.0–79.2]). Forty (38.5%) patients completed the study. The most common reasons for premature discontinuation of pasireotide were unsatisfactory therapeutic effect (n = 26, 25.0%) and adverse events (AEs; n = 20, 19.2%). Drug-related grade 3/4 AEs or drug-related serious AEs (primary endpoint) were documented in 42 (40.4%) patients, most commonly diabetes mellitus (n = 12, 11.5%) and hyperglycemia (n = 8, 7.7%). All patients experienced ≥1 AE and most (n = 102; 98.1%) reported ≥1 drug-related AE; six (5.8%) patients discontinued treatment because of hyperglycemia-related AEs. At weeks 12, 24, and 48, respectively, 36/66 (54.5%), 22/46 (47.8%), and 9/21 (42.9%) evaluable patients had normalized mUFC levels. Clinical signs/symptoms and QoL were also improved.
Conclusions: In an international, real-world, clinical-practice setting, pasireotide sc was generally well-tolerated (no new safety signals were identified), effectively reduced UFC (normalization in ~50% of evaluable patients) and improved clinical signs and QoL in patients with CD. While hyperglycemia-related AEs were common, consistent with previous studies, most were manageable, with <6% of patients discontinuing treatment because of these events.
History
References
- https://doi.org//10.1016/S0140-6736(14)61375-1
- https://doi.org//10.1530/EJE-11-1095
- https://doi.org//10.1111/j.1365-2265.1994.tb02486.x
- https://doi.org//10.1016/S2213-8587(16)00086-3
- https://doi.org//10.1210/jc.2015-1818
- https://doi.org//10.1210/jc.2012-3582
- https://doi.org//10.1016/j.ejim.2011.10.013
- https://doi.org//10.1210/er.2013-1048
- https://doi.org//10.1016/j.ecl.2018.01.006
- https://doi.org//10.4158/EP161512.DSCR
- https://doi.org//10.1210/jc.2007-2734
- https://doi.org//10.1007/s11102-016-0742-1
- https://doi.org//10.1007/s11154-008-9082-4
- https://doi.org//10.1007/s11060-013-1151-1
- https://doi.org//10.3389/fendo.2018.00164
- https://doi.org//10.1056/NEJMoa1105743
- https://doi.org//10.3389/fendo.2017.00035
- https://doi.org//10.1055/s-0042-101347
- https://doi.org//10.1007/s12020-018-1818-7
- https://doi.org//10.1007/s12020-018-1524-5
- https://doi.org//10.1530/EJE-07-0762
- https://doi.org//10.1007/s11102-013-0483-3
- https://doi.org//10.1007/s11102-016-0734-1
- https://doi.org//10.1007/s12020-017-1316-3
- https://doi.org//10.1007/BF03346419
- https://doi.org//10.1016/S2213-8587(17)30326-1
- https://doi.org//10.1111/cen.12431
- https://doi.org//10.1111/j.1365-2265.2012.04344.x
- https://doi.org//10.1210/jc.2013-3628
- https://doi.org//10.1530/EJE-17-0886
- https://doi.org//10.1210/jc.2015-2616
- https://doi.org//10.1210/jc.2011-3350
- https://doi.org//10.1159/000314224
- https://doi.org//10.1056/NEJMc1000094